Forecasting branded and generic pharmaceuticals

We forecast UK pharmaceutical time series before and after the time of patent expiry. This is a critical point in the lifecycle, as a generic form of the product is then introduced into the market, while the branded form is still available for prescription. Forecasting the numbers of units of branded and generic forms of pharmaceuticals dispensed is becoming increasingly important, due to their huge market value and the limited number of new ‘blockbuster’ branded drugs, as well as the imposed cost for national healthcare systems like the NHS. In this paper, eleven methods are used to forecast drug time series, including diffusion models (Bass model & RPDM), ARIMA, exponential smoothing (Simple and Holt), naive and regression methods. ARIMA and Holt produce accurate short term (annual) forecasts for branded and generic drugs respectively, while for the more strategic horizons of 2–5 years ahead, naive with drift provides the most accurate forecasts.

[1]  Michael Gort,et al.  Firm and Product Life Cycles and Firm Survival , 2002 .

[2]  Dennis Z. Kvesic,et al.  Product Lifecycle Management: Marketing Strategies for the Pharmaceutical Industry , 2008 .

[3]  Jaap E. Wieringa,et al.  Early Marketing Matters: A Time-Varying Parameter Approach to Persistence Modeling , 2010 .

[4]  T. Levitt.  EXPLOIT THE PRODUCT LIFE CYCLE , 1965 .

[5]  G. Tellis,et al.  Growing, Growing, Gone: Cascades, Diffusion, and Turning Points in the Product Life Cycle , 2004 .

[6]  Christopher J. Easingwood,et al.  Early product life cycle forms for infrequently purchased major products , 1987 .

[7]  Earl L. Taylor,et al.  The Diffusion of Innovation , 2013 .

[8]  Barry L. Bayus,et al.  Are Product Life Cycles Really Getting Shorter , 1994 .

[9]  Andrew T. Ching,et al.  Measuring the Informative and Persuasive Roles of Detailing on Prescribing Decisions , 2010, Manag. Sci..

[10]  A. Andreasen.  The Ghetto Marketing Life Cycle: A Case of Underachievement , 1978 .

[11]  Marc Fischer,et al.  Drivers of peak sales for pharmaceutical brands , 2010 .

[12]  Fotios Petropoulos,et al.  'Horses for Courses' in demand forecasting , 2014, Eur. J. Oper. Res..

[13]  Rosalind Masterson,et al.  Marketing : An Introduction , 2004 .

[14]  Vijay Mahajan,et al.  New Product Diffusion Models in Marketing: A Review and Directions for Research: , 1990 .

[15]  J. M. Ferrándiz,et al.  The impact of generic goods in the pharmaceutical industry. , 1999, Health economics.

[16]  Spyros Makridakis,et al.  The M3-Competition: results, conclusions and implications , 2000 .

[17]  Kenneth B. Kahn.  An exploratory Investigation of new product forecasting practices , 2002 .

[18]  K. Nikolopoulos,et al.  The theta model: a decomposition approach to forecasting , 2000 .

[19]  Qiang Liu,et al.  The Impact of Direct-to-Consumer Advertising of Prescription Drugs on Physician Visits and Drug Requests: Empirical Findings and Public Policy Implications , 2011 .

[20]  C. Croux,et al.  The Global Entry of New Pharmaceuticals: A Joint Investigation of Launch Window and Price , 2011 .

[21]  Morgan P. Miles,et al.  A research note on market creation in the pharmaceutical industry , 2011 .

[22]  C. Sismeiro,et al.  Can branded drugs benefit from generic entry? The role of detailing and price in switching to non-bioequivalent molecules , 2008 .

[23]  Ricardo Montoya,et al.  Dynamic Allocation of Pharmaceutical Detailing and Sampling for Long-Term Profitability , 2010, Mark. Sci..

[24]  D. Jain,et al.  Patent Expiry and Pharmaceutical Market Opportunities at the Nexus of Pricing and Innovation Policy , 2012 .

[25]  Kenneth B. Kahn.  An exploratory investigation of new product forecasting practices , 2002 .

[26]  Frank M. Bass,et al.  A New Product Growth for Model Consumer Durables , 2004, Manag. Sci..

[27]  W. E. Cox,et al.  Product Life Cycles as Marketing Models , 1967 .

[28]  G. Assmus.  New product forecasting , 1984 .

[29]  P. Stern.  How health managers see prescribing , 2002 .

[30]  Ambar G. Rao,et al.  Bayesian Estimation and Control of Detailing Effort in a Repeat Purchase Diffusion Environment , 1981 .

[31]  T. Aronsson,et al.  The Impact of Generic Drug Competition on Brand Name Market Shares – Evidence from Micro Data , 2001 .

[32]  J. Armstrong,et al.  Forecasting Methods for Marketing: Review of Empirical Research , 1987 .

[33]  P. Stern.  Prescriptions for branded and generic pharmaceuticals , 1994 .

[34]  A. Weil,et al.  Diffusion of Innovation , 2020, The International Encyclopedia of Media Psychology.

[35]  Gila E. Fruchter,et al.  Why the Generalized Bass Model leads to odd optimal advertising policies , 2011 .

[36]  D. Salkever,et al.  "Generic Entry and the Pricing of Pharmaceuticals" , 1995 .

[37]  Marc Fischer,et al.  Product life cycle patterns for pharmaceuticals and their impact on R&D profitability of late mover products , 2000 .

[38]  John T. Mentzer,et al.  Sales Forecasting Management: A Demand Management Approach , 2004 .

[39]  Victor J. Cook,et al.  Validity of the Product Life Cycle , 1969 .

[40]  Masataka Yamada,et al.  Forecasting with a repeat purchase diffusion model , 1988 .